CoChat

Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review

Open access
Layton, Alison M., Eady, E. Anne, Whitehouse, Heather, Del Rosso, James Q., Fedorowicz, Zbys, van Zuuren, Esther J. · 2017 · American Journal of Clinical Dermatology

The DOI matches its Crossref record; 115 of the 116 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The management of acne in adult females is problematic, with many having a history of treatment failure and some having a predisposition to androgen excess. Alternatives to oral antibiotics and combined oral contraceptives (COCs) are required. OBJECTIVE: Our aim was to conduct a hybrid systematic review of the evidence for benefits and potential harms of oral spironolactone in the management of acne in adult females. METHODS: The review was conducted according to a previously published protocol. Three reviewers independently selected relevant studies from the search results, extracted data, assessed the risk of bias, and rated the quality of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: Ten randomized controlled trials (RCTs) and 21 case series were retrieved. All trials were assessed as being at a 'high risk' of bias, and the quality of evidence was rated as low or very low for all outcomes. Apart from one crossover trial that demonstrated statistical superiority of a 200 mg daily dose versus inflamed lesions compared with placebo, data from the remaining trials were unhelpful in establishing the degree of efficacy of lower doses versus active comparators or placebo. Menstrual side effects were significantly more common with the 200 mg dose; frequency could be significantly reduced by concomitant use of a COC. Pooling of results for serum potassium supported the recent recommendation that routine monitoring is not required in this patient population. CONCLUSION: This systematic review of RCTs and case series identified evidence of limited quality to underpin the expert endorsement of spironolactone at the doses typically used (≤100 mg/day) in everyday clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40257-016-0245-x

Cites

115 of 115 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Study flow diagram
Fig. 1 Study flow diagramCC BY-NC · PubMed Central
Fig. 2 Risk of bias summary: authors’ judgments about each risk of bias item for every randomized controlled trial included. + indicates low risk, − indicates high risk, ? indicates unclear risk of bias
Fig. 2 Risk of bias summary: authors’ judgments about each risk of bias item for every randomized controlled trial included. + indicates low risk, − indicates high risk, ? indicates unclear risk of biasCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 115 references

Research works printed but not linked: 15

  1. Review Manager (RevMan) (computer program). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2014.
  2. Mansurul A, Islam AZM. Effect of spironolactone on acne vulgaris: a double blind study. Bangladesh J Dermatol Venereol Leprol. 2000;17:1–4.
  3. Wang XM, Zhang XP, Li CH. Comparative observation on the therapeutic effect of acne vulgaris with spironolactone, ketoconazole and cimetidine. J Clin Dermatol. 1991;20:303–5.
  4. Azizlerli G, Özarmagan G, Taklifi B, Südogan S, Azizlerli H. Spironolactone therapy in acne patients [Aknede spironolatone ile tedavi]. Deri Hastalıkları ve Frengi Arşivi. 1988;22:125–9.
  5. Beksac MS, Önderglu LS, Atac B. Idiopathic hirsutism with spironolactone. Adv Contracept Deliv Syst. 1990;6:265–9.
  6. Bravo Garcia M, Barroeta S. Mejia de Alejos M, Franco de Arias M, Yustiz MA, Mascia S. Use of spironoactone in patients with acne [Uso de spironolactona en pacientes con acne]. Arch Argent Dermatol. 1987;37:231–8.
  7. Anonymous. Different concentrations of spironolactone in the treatment of acne. Chinese J Dermatol. 1989;22:258-9.
  8. Devoto E, Aravena L, Rios R. Treatment of hirsutism with spironolactone and with spironolactone plus dexamethasone. Rev Med Chil. 2000;128:868–75.
  9. Molinatti GM, Messina M, Biffignandi P, Manieri C. Therapeutic possibilities in women with skin androgenic manifestations [Possibilita terapeutichein donne affette da manifestazionidi androgenizzazione a livello cutaneo]. G Ital Dermatol Venereol. 1980;115:579–84.
  10. Arenberger P, Vohradnikova O, Zaruba F. Treatment of acne vulgaris with spironolactone. Cesk Dermatol. 1988;63:224–7.
  11. Cortez de Castro G, Pacheco A, Naranjo H, Palacios A. Acnevulgaris: treatment with spironolactone [Acne vulgar: tratamiento con espironolactona]. Salus Militia. 1987;12:34–7.
  12. Havrenne JED, Halbe HW. Treatment of idiopathic hirsutism with spironolactone [Tratamento do hirsutismo idiopático com espironolactona]. Ginecol Obstet Bras. 1985;8:73–4.
  13. Vohradnikova O, Arenberger P, Kratochvilova M, Zaruba F. Treatment of acne vulgaris with spironolactone and Androcur. Cesk Dermatol. 1988;63:308–10.
  14. Yemisci A, Gorgulu A, Piskin S. Spironolactone therapy in acne vulgaris [Acne vulgaris tedavisinde spironolakton]. Türkderm Deri Hastaliklari ve Frengi Arivi. 1994;28:209–12.
  15. Nast A, Bayerl C, Borelli C, et al. S2 k-guideline for therapy of acne [in German]. J Dtsch Dermatol Ges. 2010;8(Suppl 2):1–59.

Cited by

See all 135

Metadata

Authors
Layton, A. M., Eady, E. A., Whitehouse, H., Del Rosso, J. Q., Fedorowicz, Z., & van Zuuren, E. J.
Affiliations
Harrogate and District NHS Foundation Trust (GB)
Corresponding author
Eady, E. Anne
Venue
American Journal of Clinical Dermatology
Published
2017-02-02
Volume
18
Issue
2
Pages
169-191
ISSN
  • 1175-0561 (ISSN-L)
  • 1179-1888
OpenAlex
W2585329337
Cited by
126
References
116
Citations by year
2026: 9 · 2025: 7 · 2024: 20 · 2023: 15 · 2022: 20 · 2021: 15 · 2020: 19 · 2019: 11 · 2018: 6 · 2017: 2
FWCI
1.86
Type
journal article
Language
en
Open access
Locations
  • American Journal of Clinical Dermatology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Dermatology › Acne and Rosacea Treatments and Effects
  • Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
Keywords
spironolactone, acne, adult female acne, hyperandrogenism, combined oral contraceptives, serum potassium monitoring, treatment efficacy, risk of bias
MeSH terms
Acne Vulgaris, Administration, Oral, Adult, Mineralocorticoid Receptor Antagonists, Androgens, Anti-Bacterial Agents, Contraceptives, Oral, Combined, Female, Humans, Sebaceous Glands, Spironolactone, Randomized Controlled Trials as Topic, Treatment Failure, Hyperandrogenism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review. https://app.cochat.ai/papers/10.1007/s40257-016-0245-x
The paper
Layton, A. M., Eady, E. A., Whitehouse, H., Del Rosso, J. Q., Fedorowicz, Z., & van Zuuren, E. J. (2017). Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-016-0245-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.